Neuroinflammation in COVID-19 and Depression

Inclusion Criteria: * Age 18 to 80 * Diagnosis of COVID-19 * Recovered from mild or moderate COVID-19 symptoms. Mild is defined as no evidence of pneumonia or hypoxia. Moderate is defined as presence of clinical symptoms of pneumonia but not severe enough to require ongoing use of supplementary oxygen. * Recovered from physical COVID-19 symptoms including cough, shortness of breath, fever, chills, or gastrointestinal upset for at least 4 weeks * New onset major depressive episode (MDE) within 3 months after COVID-19, as verified by the Research Version of Structured Clinical Interview for DSM 5 (SCID-5-RV) * High-affinity-binder (HAB) or mixed-affinity-binder (MAB) genotype for rs6971 polymorphism, based on saliva genetic testing Exclusion Criteria: * Lifetime history of an autoimmune disease * Lifetime history of a neurological disease, excluding migraine * Lifetime diagnosis of Antisocial or Borderline Personality disorder * Lifetime history of psychotic symptoms prior to COVID-19 * Lifetime diagnosis of Substance of Alcohol Use Disorder * Use of street drugs, including marijuana, in the past two months * Presence of cigarette smoking in the past two months * Positive urine drug or cotinine screen at any timepoint during the study * Currently pregnant * Currently breastfeeding * Use of aspirin or ibuprofen within the past 2 weeks * Use of any other anti-inflammatory medication or MAO-B inhibitors within the past 4 weeks * Use of herbal remedies in the past month * Presence of metal implant, object or electrical devices that are contraindicated for MRI * Current disorders of coagulation, blood or ongoing use of anticoagulant medication * Claustrophobia * Weight over 400lbs and height over 7ft * History of undergoing a number of PET scans that will lead participants to exceed the annual (20mSv) / lifetime (8 PET scans) radiation by completing this study * Current participation in another research study